Jul 05, 2013, 11.10 PM | Source: CNBC-TV18
CNBC-TV18's Payaswini Upadhyay reports that pharma companies, Hospira and Mylan were forced to modify non-compete clauses to receive the CCI's permission to go ahead with their acquisitions.
Payaswini Upadhyay (more)
Reporter, CNBC-TV18 |
Also Read: PMO seeks clarification on Jet-Etihad deal
In both the deals, Competition Commission of India concluded that though the acquisitions would cause no adverse affect on the domestic market, it objected to the duration and scope of the non-compete clauses.
Orchid and its promoter were prohibited from competing in the same business for eight and five years respectively. To get the deal cleared by CCI, the parties had to modify the duration to five years. In Mylan-Strides deal, the proposed duration was six years which again had to be modified to four years.
The second aspect CCI objected to was the scope of the non-compete clause. Hospira had to place put restrictions on Orchid and its promoters from conducting research and development (R&D) and testing of two APIs.
The CCI gave the deal a go-ahead only after the clause was modified to allow Orchid to conduct R&D and testing on new molecules which are currently non-existent worldwide.
Mylan's non-compete clause sought to impose three restrictions on Strides, its group companies and promoters —a blanket restriction covering injectable products across all therapeutic categories; products in the oncology and ophthalmic categories that Strides did not manufacture, and development of new molecules which are presently non-existent.
CCI observed that a non-compete clause should cover only those products for which the target is either in the process of developing, manufacturing or selling.
Regarding the CCI's concerns being restricted to the pharma sector alone, legal experts add that there have been deals with non-compete clauses of six and even eight years duration that have been cleared by CCI.
So, this could be a sign of extreme caution by the CCI is due to the government's concerns with regards to influx of foreign companies into India's pharmaceutical sector.
But till the regulator makes its stance clear on non-compete clause, it is difficult to arrive at a conclusion.
Short Strides Shasun, Canara Bank; buy Voltas: Rahul Shah
Rahul Shah of Motilal Oswal is of the view that on
Strides Shasun's Q3 results on Feb 08, 2016
Strides Shasun Ltd has informed BSE that a meeting
Strides Shasun: Updates on acquisition of seven brands from Johnson & Johnson
With reference to the earlier announcement dated O
Strides Shasun receives CCI approval for acquisition of CNS divisions of Ranbaxy
Strides Shasun Ltd has now informed BSE that that
Strides Shasun gets CCI nod to buy 7 brands of J&J
Stay invested in Strides Shasun, says Gaurang Shah
Gaurang Shah of Geojit BNP Paribas Financial Servi
AB InBev gets CCI nod to acquire SABMiller
Marriott-Starwood deal gets CCI nod
Post deal, estimated to be worth about USD 12.2 bi